Samik Basu
About Samik Basu
Samik Basu Career at Cabaletta
Samik Basu is the Chief Scientific Officer at Cabaletta, a position he has held since December 2019. Before his current role, he served as Vice President of Preclinical Research and Translational Medicine within the same company. His tenure at Cabaletta is marked by significant contributions to the company’s scientific and translational research initiatives.
Previous Roles of Samik Basu
Before joining Cabaletta, Samik Basu was the Head of Translational Sciences (Medicine) at Adaptimmune Therapeutics, plc. His previous roles also include significant positions at Merck Research Laboratories, where he co-led the preclinical development efforts for the immunotherapy drug Keytruda (pembrolizumab).
Samik Basu’s Expertise and Experience
Samik Basu has 17 years of experience in the fields of adoptive immunotherapy, translational research, autoimmunity, and tumor immunology. His career has spanned both industry and academia, providing a robust foundation in scientific and medical research.
Samik Basu's Professional Background
Samik Basu has previously held roles at prestigious institutions such as the National Institutes of Health, Albert Einstein College of Medicine, and the University of Pennsylvania. His diverse background underscores a deep involvement in various aspects of medical research and clinical pathology.
Education and Training of Samik Basu
Samik Basu holds an M.D. from Temple University and completed his residency training in Clinical Pathology. His medical education and subsequent training have provided him with a strong foundation in clinical and translational sciences.